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Hepatocyte Nuclear Factor 4
Is a Transcription Factor that
Constitutively Binds Fatty Acids
Its expression pattern is more ubiquitous, but high levels
are detected in the liver and islets, and in the brain [11].
Conflicting evidence has been reported on the puta-
tive role of palmitoyl CoA as a ligand for HNF4 [12, 13].
As palmitoyl CoA is much larger than many other nuclear
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GlaxoSmithKline Inc. receptor ligands [14], an initial goal of our structural
studies was to determine whether the HNF4 binding5 Moore Drive
Research Triangle Park, North Carolina 27709 pocket was consistent with properties of this noncon-
ventional ligand.
Crystal structure determination was attempted for the
C-terminal ligand binding domains (LBDs) of HNF4 andSummary
HNF4. HNF4 LBD (amino acids 103–408) crystallized
readily, yielding diffraction data to 2.7 A˚. The X-ray struc-The 2.7 A˚ X-ray crystal structure of the HNF4 ligand
ture of HNF4 LBD showed the presence of an unex-binding domain (LBD) revealed the presence of a fatty
pected small molecule in the binding pocket, which wasacid within the pocket, with the AF2 helix in a confor-
determined to be a mixture of fatty acids by gas chroma-mation characteristic of a transcriptionally active nu-
tography/mass spectrometry (GC/MS). Analysis of ex-clear receptor. GC/MS and NMR analysis of chloro-
tracts from purified HNF4 LBD showed a similar set ofform/methanol extracts from purified HNF4 and
bound fatty acids. In vitro, HNF4 constitutively bindsHNF4 LBDs identified mixtures of saturated and cis-
nuclear receptor coactivators, and in vivo studies indi-monounsaturated C14-18 fatty acids. The purified
cate that both HNF4 subtypes are constitutively active.HNF4 LBDs interacted with nuclear receptor coactiva-
The HNF4/fatty acid interactions differ significantly fromtors, and both HNF4 subtypes show high constitutive
other nuclear receptor/fatty acid complexes. The resultsactivity in transient transfection assays, which was
are consistent with endogenous fatty acids being consti-reduced by mutations designed to interfere with fatty
tutively bound to HNF4 and HNF4.acid binding. The endogenous fatty acids did not
readily exchange with radiolabeled palmitic acid, and
Resultsall attempts to displace them without denaturing the
protein failed. Our results suggest that the HNF4s may
Structure of HNF4be transcription factors that are constitutively bound
Constructs containing amino acids 103–408 of HNF4to fatty acids.
and 142–465 of HNF4 were subcloned into the E. coli
expression vector pRSETa (Invitrogen) with a His-tag
Introduction sequence engineered at the protein’s N terminus. The
soluble protein was purified by Ni2 NTA affinity chroma-
The nuclear hormone receptors can be generally tography, followed by anion exchange, and finally size
classed into two groups, the “classical” receptors, exclusion chromatography. Protein sequence and purity
which were identified from their ability to bind a pre- were confirmed by N-terminal sequencing and mass
viously identified hormone, and the “orphan” receptors, spectrometry to greater than 95% homogeneity. HNF4
for which a ligand has not been determined [1]. The crystallized readily from ammonium phosphate in the
hepatocyte nuclear factor 4 (HNF4) class of orphan re- space group I4122 with unit cell axes of a b 152.71 A˚,ceptor contains two subtypes in humans, HNF4 c  93.42 A˚, yielding diffraction data to 2.7 A˚. The struc-
(NR2A1) and HNF4 (NR2A2). HNF4was originally iden- ture was initially phased using a methyl-mercury chlo-
tified from its ability to bind the HNF1 promoter [2]. ride derivative to generate single isomorphous replace-
Heterozygous mutations in HNF4 have been linked to ment anomalous scattering (SIRAS) data.
the disease mature onset of diabetes of the young type 1 Although mass spectrometry confirmed that crystals
(MODY1), in which individuals show defects in glucose- contained full-length HNF4 LBD (amino acids 103–408),
stimulated insulin secretion as well as reduced serum only amino acids 103–119 and 124–327 were visible in
triglycerides [3]. HNF4 has been shown to regulate the the electron density map. The C-terminal F domain was
expression of several apolipoprotein genes [3–5], as well not seen, suggesting that there are no strong interac-
as other factors involved in glucose metabolism and tions between this domain and the “core” LBD, as is
insulin secretion [6–9]. Consistent with its role in the observed for PR and AR [15, 16]. The overall architecture
regulation of insulin secretion and triglyceride metabo- of the HNF4 LBD was similar to other members of the
lism, HNF4 is expressed in the pancreatic islets and nuclear receptor family (Figures 1A and 1C). There were
the liver [2, 7]. Recent data suggest that HNF4 may 10  helices arranged in a three-layer sandwich, with
also regulate hepatic glucose production [10]. HNF4 helices 4, 5, 8, and 9 sandwiched between helices 1 and
was identified from DNA sequence homology to HNF4 3 on one side, and 10/11 on the other side. There was
[11]. The physiological role of HNF4 is less understood.
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Figure 1. Structure of HNF4 and Ligand Detection
(A) Ribbon diagram of HNF4 with bound palmitate. Palmitate has dark gray carbon atoms and red oxygen atoms.
(B) Composite-omit map of the binding pocket of HNF4 contoured at 1.2  showing electron density from bound ligand.
(C) Primary sequences of HNF4 and  with secondary structure and proposed ligand contacts.  helix, orange;  sheet, green. Blue HNF4
residues are van der Waals contacts; magenta HNF4 residues are hydrogen bonds with palmitic acid; red HNF4 residues are mutations
found in MODY1 patients.
no helix 2 in HNF4. HNF4 is most similar to the holo nuclear receptor LBD dimers: buried hydrophobic sur-
face for stability, with hydrogen bonds and charge pair-retinoid X receptor  (RXR, NR2B1) [17, 18], with an
rmsd between corresponding C atoms of 1.00 A˚ for ing for specificity. As a dimer, HNF4 buries 1320 A˚2 of
accessible surface per monomer, between the 1266 A˚2all residues contained in helices 3 through 11. These
residues contain the conserved structural motifs ob- and 1632 A˚2 observed for RXR and ER homodimers,
respectively. The HNF4 homodimer interface includesserved in other nuclear receptor LBDs. The AF2 helix of
HNF4 (amino acids 317–326) was found in the “active” specific side chain/side chain interactions, with hydro-
gen bonds between Q267-E287 and Q296-Q296 and saltconformation characteristic of agonist-bound nuclear
receptors. bridges between E229-K260 and possibly D272-R282.
LBD interactions disrupt the formation of HNF4/RXRThe HNF4s are known to be obligate homodimers [19],
with the LBD responsible for partner selectivity [20]. heterodimers [20] by preventing the formation of re-
quired salt bridges. The RXR equivalent to HNF4 E229HNF4 and HNF4 LBD behaved as dimers in size-
exclusion chromatography, and HNF4 crystallized with and K260 are D359 and E390, respectively, so a hetero-
dimer will create one unfavorable pairing. HNF4 D272the dimer axis coincident with a crystallographic 2-fold.
The HNF4 homodimer interface is composed of resi- and R282 are equivalent to RXR A402 and P412, re-
spectively, with no charge pairing possible. Also, thedues in helices 7, 9, and 10, and is the same interface
seen in other nuclear receptor homo- and heterodimers critical heterodimer salt bridge observed between RXR
R393 and PPAR D441 cannot be made to HNF4, where[17, 18, 21–23]. Of the 22 residues involved in HNF4
dimerization, 20 are conserved in HNF4, and all the equivalent residue is a Thr. The importance of the
E229-K260 salt bridge for homodimer formation wascharged residues in the HNF4 dimer interface are iden-
tical in HNF4. This conservation of interface residues observed previously by Bogan et al. [13], who demon-
strated that wild-type HNF4 cannot form heterodimerssuggests that HNF4/HNF4 heterodimers could exist
in tissues where both proteins are expressed. The HNF4 with HNF4 mutants where residues E327 (E287) and
K300 (K260) are changed to their RXR equivalents.homodimer interface exemplifies themes seen in other
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primarily C16:0 (palmitic) and C16:1 fatty acids, althoughTable 1. Crystallographic Data and Refinement
some C17:1, an uncommon fatty acid in E. coli [24], was
Crystal MeHgCl Native also observed (Figure 2A). Atoms C1–14 of the fatty acid
Resolution range 40.–3.0 (3.1–3.0) 50.–2.7 (2.8–2.7) are visible in the HNF4 structure. The lack of electron
Observations (unique) 413,191 (10,558) 1,308,098 (18,866) density for the remaining atoms is likely due to the mix-
Completeness (outer shell) 99.6 (100) 98.4 (93.7) ture of fatty acids present in the crystals.
I/s (outer shell) 36.3 (3.3) 35.8 (3.5) The sequence homology between HNF4 subtypes
Rmerge percent (outer shell) 7.8 (44) 4.8 (32) (Figure 1C) suggested that HNF4 might also bind fatty
Refinement Statistics acids. E. coli-expressed HNF4 LBD was purified using
Ni2 NTA chromatography and bound ligands were puri-Resolution range 50.–2.7
Percent Rfree 7 fied by chloroform/methanol extraction. GC/MS analysis
Rcryst (Rfree) 24.8 (26.8) of the methyl esters from these extracts indicated that
Protein atoms 1,774 HNF4 also bound a mixture of saturated and monoun-
Ligand atoms 18
saturated C16–18 fatty acids (Figure 2B). Myristic, pal-Water molecules 15
mitic, oleic, and stearic acids were readily identified byRmsd bonds/angles 0.0085/1.675
comparison with standards. The position of the doubleAverage protein B factor 70.1
bond for the unsaturated C16 and C17 fatty acids was
Rcryst  |Fobs  Fcalc|/Fobs determined by EI analysis of the picolinyl ester deriva-Rmerge  |I  I|/I
tives of the fatty acids (Figure 2C). In both cases, it was
determined to be at the 	9 position.
To obtain an independent evaluation of the fatty acid
HNF4 LBD Contains a Fatty Acid structure, NMR analysis was carried out on a 34 mg
within the Protein sample obtained by chloroform/methanol extraction
Remarkably, electron density was observed in the from 2.4 g of purified HNF4 LBD. The major component
HNF4 pocket in the first solvent-flattened SIRAS map of the large-scale extract was a monounsaturated fatty
that could not be accounted for by the protein. During acid. The heteronuclear couplings between the olefinic
the course of model refinement, the pocket density im- protons and the allylic carbons observed in the HMBC
proved and appeared consistent with a thin curved mol- spectrum (heteronuclear multiple-bond correlation) indi-
ecule (Figure 1B; Table 1). The data suggested that cated that the substituents on the double bond are cis
HNF4 contained an organic compound that was cap- [25, 26]. Although the sample contained a mixture of
tured during the expression of the protein and remained fatty acids, there were no peaks in the HMBC spectrum
bound during the process of purification and crystalli- indicative of trans double bonds. Determination of the
zation. location of the double bond was accomplished using a
HNF4 contains a ligand binding pocket, which is a TOCSY-HETCOR experiment [27, 28], which correlates
well-defined hydrophobic cavity with a volume of 626 A˚3 each proton with its directly attached carbon and with
and an arginine residue (R187) at one end. This pocket other carbons in the same spin system (Figure 3). Three
is solvent accessible, with a potential ligand access site slices through the TOCSY-HETCOR spectrum of the un-
between the  turn and helix 3, as was observed for saturated fatty acid, taken at the chemical shift of the
PPAR [23]. A prominent feature of the pocket was a methyl protons, the protons adjacent to the carboxylic
direct contact between M143 in helix 3 and M302 in acid, and the allylic protons of the double bond, revealed
helix 11. This contact bridged the binding pocket and all 15 of the protonated carbons. Making the assumption
effectively blocked direct ligand access to residues 317– that the allylic proton correlation peaks in the bottom
326 in helix 12. Electron density for the endogenous slice in Figure 3B are divided equally between each side
compound started adjacent to R187, curved around the of the double bond, then the TOCSY-HETCOR spectrum
M143–M302 bridge, and proceeded straight toward indicates that the double bond is between C9 and C10.
V315 (Figures 1B and 5). These features suggested the The identity of the unknown was subsequently con-
presence of a lipophilic acidic molecule within the firmed by comparison of its 13C spectrum with that of a
pocket. standard sample of palmitoleic acid (Figure 3A). Thus,
To determine the identity of the contents of the HNF4 two analytical methods independently identified the
pocket, a purified preparation of HNF4 LBD was ex- HNF4 ligands as 	9 monounsaturated fatty acids, with
tracted with chloroform/methanol (2:1) to isolate any the NMR revealing that the double bond is in the cis
bound organic compound(s). Initially, gas chromatogra- configuration.
phy/mass spectrometry (GC/MS) analysis of the extract
showed the characteristic tailing profile of a negatively
charged substrate. The extract was then treated with HNF4s Are Constitutively Active
The fact that both HNF4 subtypes bind a variety of fatty3% (v/v) acetyl chloride in methanol to convert any car-
boxylic acids groups to their corresponding methyl es- acids and that HNF4 crystallized with AF2 in the active
configuration, suggested these receptors might beters. The derivatized sample was analyzed by GC/MS
using both electron impact ionization (EI) and chemical bound to endogenous fatty acids within cells, interact
readily with coactivators, and be constitutively activeionization (CI). The molecular weights for the constit-
uents in the HNF4 extract, determined from the CI data, as transcription factors. First, we determined whether
the purified HNF4 and HNF4 LBDs could constitu-were consistent with their identification as methyl esters
of saturated and monounsaturated C14–18 fatty acids, tively recruit nuclear receptor coactivators. Figure 4A
Structure
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Figure 2. Mass Spectroscopy Determination
of HNF4 Ligands
The HNF4 extracts were converted to methyl
esters and analyzed by GC/MS in CI mode
using isobutane reagent gas for ionization to
determine molecular weights. Fatty acid
chain lengths and saturation states are indi-
cated. Myristic, palmitic, oleic, and stearic
acids were readily identified by comparison
to standards.
(A) GC/MS analysis of the HNF4 extract.
Fatty acid chain lengths and saturation states
are indicated.
(B) GC/MS analysis of the HNF4 extract.
Fatty acid chain lengths and saturation states
are indicated.
(C) The position of the double bond is indi-
cated by a 2 Da shift in the EI fragment ion
pattern of the picolinic acid derivative, this
double bond is located at C9. The double
bond of the C17:1 fatty acid was also at C9.
shows the results of a fluorescence resonance energy receptor coactivator and their potential to act as consti-
tutively active transcription factor.transfer (FRET) experiment designed to measure the
interaction of E. coli-expressed and purified HNF4with HNF4 could interact readily with nuclear receptor co-
activators, but was this interaction sufficient to causethe second LXXLL motif (amino acids 685–710) of the
nuclear receptor coactivator SRC-1. HNF4 bound the constitutive activity in vivo? To test this hypothesis, we
compared the transcriptional activation of wild-type re-SRC-1 peptide without the addition of an exogenous
ligand, demonstrating its ability to interact with a nuclear ceptors with mutants designed to inhibit fatty acid bind-
Figure 3. NMR Determination of HNF4 Li-
gand Structure
The 13C reference spectrum of palmitoleic
acid is plotted (A) above slices from the
TOCSY-HETCOR spectrum of the purified
HNF4 fatty acid ligand (B). The three slices
(top to bottom) are carbons correlated to: the
methyl protons, the protons  to the carbox-
ylic acid, and the allylic protons. These slices
revealed all 15 of the protonated carbons.
Making the assumption that the allylic proton
correlation peaks in the bottom slice are di-
vided equally between each side of the dou-
ble bond, then the TOCSY-HETCOR spec-
trum indicates that the double bond is
between C9 and C10.
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ing in their ability to activate transcription on the HNF1
promoter in CV1 cells (Figure 4B). Both HNF4 subtypes
exhibited high basal activity, consistent with constitutive
activation by these receptors. Replacing the binding
pocket arginine with a glutamic acid, methionine, or
alanine residue decreased, but did not completely elimi-
nate, transcriptional activity. These mutant HNF4 LBDs
were expressed in E. coli and purified in parallel with
wild-type protein. Thermal denaturation studies indi-
cated that the mutant receptors were significantly less
stable than the wild-type protein (data not shown). These
observations were consistent with the mutant receptors
having a reduced capacity to bind to endogenous fatty
acids and the fatty acids playing a structural role in
HNF4 folding.
Endogenous Fatty Acids Cannot Be Displaced
from HNF4
Along with the transactivation experiments, many at-
tempts were made to displace the endogenous fatty
acids from HNF4 LBD and measure the binding con-
stant. Purified HNF4 and HNF4 LBD at 0.5 
M were
incubated with a 10-fold excess molar ratio of 14C pal-
mitic acid at various temperatures (on ice, 4C, 25C,
30C, and 37C) and for several time points (4, 12, 24,
48, 72, and 168 hr). The unincorporated 14C palmitic acid
was separated from the protein using a G-25 column.
None of the 14C palmitic acid was found associated with
the HNF4 protein.
One possibility was that the endogenous fatty acid
has a very slow off-rate, preventing our detection of
ligand exchange. We repeated the ligand exchange ex-
periment outlined above but used purified HNF4 LBD
that was dialyzed in 1000-fold excess buffer for 72 hr
at 4C. The dialyzed HNF4 LBD was then incubated with
either 14C palmitic acid or 14C stearic acid and separated
from unincorporated fatty acid with a G-25 column.
Again, none of the 14C labeled fatty acid was associated
with the HNF4 protein.
To determine if the lack of incorporation of labeled
fatty acids into HNF4 was due to the inability of the
endogenous fatty acid to dissociate from the receptor,
we tried to increase the off-rate by partially denaturing
the HNF4 protein. HNF4 was treated with increasing
Figure 4. HNF4 Interacts with Coactivators In Vitro and Is Constitu-
tively Active in Cells
(A) Binding of HNF4 to SRC-1. This figure shows the results of a
FRET experiment measuring direct contact between labeled HNF4
and labeled SRC-1 peptide. Increasing amounts of unlabeled HNF4
was added to the mixture to compete off the labeled peptide. CV-1
cells were transfected with the HNF1x3-tk-CAT reporter vector in
the presence of no receptor expression plasmid, expression plasmid
containing wild-type HNF4, or expression plasmids containing HNF4
with the binding pocket arginine mutated. Cell extracts were subse-
quently assayed for CAT activity. An internal control plasmid was
used to correct for any differences in transfection efficiency between
wells. Data represent the mean of assays performed in quadrupli-
cate SD.
(B) No receptor compared to HNF4 wild-type, R187E, R187M,
R187A.
(C) No receptor compared to HNF4 wild-type, R227E, R227M,
R227A.
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amounts of urea (0, 2, 4, and 6 M), while the protein was in helix 3 and to other pocket residues through bound
water molecules. The directly contacted glutamine isimmobilized on a metal chelating column. The protein
was flushed with 10 column volumes of buffer containing not conserved in either ROR or ROR. By contrast, the
HNF4 pocket is almost exclusively hydrophobic, withthe appropriate concentrations of urea to help remove
the endogenous fatty acid from the receptor. The HNF4 the exception of the conserved arginine that interacts
directly with the fatty acid. Palmitic acid almost fills theLBD protein was eluted from the column with an imidaz-
ole gradient and incubated at 2.5 
M with a 5-fold molar HNF4 binding pocket; there is not room for additional
bound water molecules.ratio (12.5 
M) of labeled 14C palmitic acid for 4 hr at
room temp. The urea concentration was slowly reduced The HNF4 structure showed the fatty acid with its
acid head-group forming a hydrogen bond with a con-to allow the receptor to refold in the presence of the
labeled fatty acid. Each sample was divided in half, one- served arginine in helix 5, much like the binding mode
of oleic acid to the constitutively active RXR mutant [17]half was centrifuged over a G-25 column and counted
on the scintillation counter and the other was run on a (Figures 1A and 5). The acid binding mode seen in HNF4
is also similar to that of RAR and TR. Two methioninesnative 4% polyacrylamide gel. The gel was dried and
the band corresponding to the HNF4 protein was cut in the HNF4 binding pocket prevent a direct interaction
between the fatty acid and the AF2 helix. The volumesout and counted in the scintillation counter. Again, there
were no 14C palmitic acid counts associated with the of the PPAR and ROR ligand binding pockets (1400 A˚3
and 766 A˚3, respectively) are much larger than the HNF4HNF4 protein.
pocket (626 A˚3), which is only 20% larger than the 520 A˚3
calculated for RAR. Unlike HNF4, the volumes of the
Discussion PPAR and ROR binding pockets are significantly larger
than the fatty acids. The HNF4s only bind C14–18 satu-
The structures of several orphan nuclear receptors have rated and monounsaturated fatty acids, with the ligand
recently been obtained as a complexes with various almost completely filling the pocket (Figure 5). The vol-
naturally occurring lipids, including peroxisome prolifer- ume occupied by a molecule of palmitic acid lies some-
ator-activated receptor delta (PPAR), retinoic acid- where between the molecular volume of 240 A˚3 and the
related orphan receptor  (ROR), the Drosophila RXR accessible volume of 822 A˚3. Although the average B
paralog USP [29, 30], and a constitutively active mutant factor of the ligand (85.8) is 21% greater than the average
RXR [17]. However, all of these reveal significant differ- protein B factor, this is probably because a mixture of
ences with HNF4 in the role of the fatty acid within the fatty acids is bound to both HNF4s, as revealed by GC/
binding pocket. The open conformation of USP bound MS. These differences suggest that the fatty acid bound
to phospholipid is significantly different from other li- within the HNF4s may serve a different biological func-
ganded nuclear receptors, making it difficult to compare tion compared to the PPARs and the RORs.
binding pocket interactions with HNF4. The PPAR We found that an endogenous fatty acid was bound
structure [31] shows the fatty acid eicosapentaenoic to the purified HNF4, which was sufficient to promote
acid (EPA) bound with the acid head-group orientated interaction with nuclear receptor coactivators. The con-
toward the C terminus, where it makes a hydrogen bond stricted fit within the binding pocket suggests that the
directly with a residue in the AF2 helix. The large PPAR fatty acid is bound tightly to HNF4. In fact, all of our
ligand binding pocket even allows EPA to adopt multiple attempts to measure HNF4 ligand exchange with radio-
conformations within the pocket. The size differences labeled palmitic acid have shown that either exchange
in the volume of the binding pockets may explain the does not occur or the rate is extremely slow under the
differences in the fatty acid binding profiles of these conditions examined. The likelihood that bound fatty
nuclear receptors. The PPARs are relatively promiscu- acids do not readily exchange agrees with the observa-
ous, binding a wide range of saturated and unsaturated tion that the composition of fatty acids extracted from
fatty acids, with PPAR and PPAR preferentially bind- HNF4 does not match the composition of fatty acid
ing long chain polyunsaturated fatty acids [31]. Notably, components in E. coli. For example, the C17:1 fatty acid,
the EPA-PPAR cocrystal structure was obtained only which is a minor component in E. coli, is a significant
after the addition of saturating concentrations of the component of HNF4 extracts. One can speculate that
fatty acid to the protein. The apo-PPAR crystal struc- the fatty acid goes through a selection process during
ture showed that there was no endogenous fatty acid HNF4 translation and folding and is then trapped in the
bound within the pocket [23]. Thus, fatty acids appear fully folded protein. Thereafter, the fatty acid does not
to be bone fide ligands for the PPARs, with the ability behave like an exchangeable ligand, but rather as a
to modulate the activity of the receptor by the rise and structural cofactor for HNF4.
fall of their concentrations within cells. Surprisingly, we found that HNF4 AF2 was in the active
The ROR structure [32] showed that stearic acid oc- conformation even though it does not directly interact
cupied 33% of the volume of the receptor binding with the fatty acid. The amphipathic nature of helix 12
pocket. The authors attributed the presence of the fatty is mostly responsible for the observed packing against
acid as a fortuitous event during protein expression and the body of the receptor. The only polar interaction that
purification. The ROR pocket had a hydrophobic side, stabilizes the position of the AF2 is between Lys309 in
which was partially occupied by the stearic acid chain, helix 11 and Gln321 in helix 12. However, these two
and a polar side, which was occupied by the fatty acid residues are on the protein surface, so the interaction
head group and 11 bound water molecules. The carbox- is probably weak. Helix 12 sits in a hydrophobic cleft
created by helices 3 and 11. It is possible that the fattyylate group of the fatty acid interacts directly with Q265
HNF4 Binds Fatty Acids
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Figure 5. The HNF4 ligand binding pocket
Model showing proposed interactions be-
tween palmitic acid and the HNF4 binding
pocket. HNF4 atoms are yellow except for
arginine 187 (blue). Palmitic acid has white
carbons and red oxygens. The Connolly sur-
face on the inside of the pocket is shown in
green. C16–C18 fatty acids fully occupy the
pocket.
acid aids the formation of this cleft through interactions The possibility that HNF4 is saturated by endogenous
ligands may explain the results of Figure 2 in Hertz etwith residues in helix 11 and 3. In fact, the two methio-
nines (M142 and M301) that span the pocket and interact al. [12], that high concentrations of palmitic acid are
required to obtain a modest increase in HNF4 activitydirectly with the fatty acid may play a role in stabilizing
the ligand binding domain in an active conformation. in COS-7 cells. In that study, high concentrations of
longer chain or polyunsaturated fatty acids either de-Thus, it appears the presence of the fatty acid within
the protein serves to bring the two outer layers of the crease basal activity or leave it unchanged.
There are inconsistent reports in the literature about“-helical sandwich” closer together to form the com-
plementary hydrophobic cleft adjacent to helix 12. the binding of palmitoyl CoA to HNF4. The authors that
first claimed that palmitoyl CoA activated HNF4 [12]While we don’t know the relevant HNF4 fatty acid in
mammalian tissues at this point, we do know that HNF4 later claimed that it inhibited HNF4 [37]. However, other
laboratories have been unable to reproduce these re-is highly conserved throughout the animal kingdom,
making it likely that the ligand is conserved as well. sults. Importantly, Bogan et al. [13] recently demon-
strated that the association of palmitoyl CoA with HNF4Although the average pairwise sequence identity of
known HNF4 LBDs is 62.2%, the 26 binding pocket resi- was nonspecific and was most likely due to increased
solubilization of the protein. These results would be con-dues are highly conserved except for a single residue:
HNF4 A216 (HNF4 S256) which is restricted to a Gly, sistent with our structural data that the CoA thioester
is too large to fit within the protein as a conventionalAla, or Ser. Thus, it is likely that the fatty acids bound
to HNF4 are also conserved throughout the animal king- ligand.
The atomic structure of HNF4 LBD encompassesdom [33].
The idea that HNF4 is constitutively bound to a fatty four of the mutations in HNF4 responsible for MODY1
[38]. The truncations at R154 (R113) and Q268acid is consistent with protease digestion experiments
of Bogan et al. [13]. In these experiments, several nu- (Q228) do not require structural analysis. They occur
at the ends of helix 1 and helix 7, respectively, andclear receptors were expressed in vitro using rabbit re-
ticulocyte lysate, labeled with 35S, and digested with produce a protein without a functional LBD, unable to
be modulated by ligand. The mutation V255M (V215)trypsin either alone or in the presence of known or puta-
tive ligands. Digestion of PPAR and RAR required alters a residue in direct contact with the ligand. The
added bulk of the methionine could potentially impingethe addition of exogenous ligands to yield the 30 kDa
protected fragment characteristic of the intact LBD [34]. on the binding pocket and interfere with fatty acid bind-
ing. The effect of the mutation E276Q (E236) is subtler.Only HNF4 digestion gave rise to a 30 kDa fragment in
the absence of added ligand. Thus, HNF4 synthesized The negatively charged E236 forms two hydrogen bonds
with R284 (R324). This has the effect of connectingby a different expression system may have a constitu-
tively bound fatty acid ligand. helix 8 to helix 10 and neutralizes the positive charge
of R284, which is less than 4 A˚ from R277 (R317).Constitutive transcriptional activity for both HNF4
subtypes was observed in this study and others [35, 36] Changing the glutamate to a glutamine both reduces the
hydrogen bonds and removes the charge neutralization,have observed constitutive activation by HNF4. This
constitutive activity can be reduced by mutating binding potentially destabilizing the protein. These predictions
of the effect of the MODY mutations are in general agree-pocket residues (Figure 4) and is consistent with the
receptors being activated by endogenous fatty acids. ment with the functional analysis of HNF4 by Lausen et
Structure
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with 1 mM methyl mercury chloride yielded suitable crystals foral. [35]. They see complete ablation of HNF4 function
phase determination. The final 2.7 A˚ native and 3.0 A˚ derivative databy the R154X and Q286X mutations, as well as a de-
sets were collected on the undulator beam-line 17ID at the APScrease in transactivation ability of the E276Q mutant.
using a MARCCD detector. All data reduction was performed using
Their analysis of the V255M mutant shows a more com- HKL2000, with results summarized in Table 1.
plex functional phenotype, with decreased activity at
low level but increasing to wild-type activity at higher Structure Determination and Refinement
transfection levels. The amino acids in the HNF4 bind- The structure was solved using single isomorphous replacement
ing pocket and HNF4 mutations responsible for anomalous scattering (SIRAS) from the methyl-mercury chloride de-
rivative. Mercury sites were found using Shake and Bake [41], andMODY1 are shown in Figures 1C and 5.
phases were refined by SHARP [42] and improved by solvent flippingA novel mode of action for HNF4 is suggested by the
[43], which produced traceable electron density. Models were builtobserved active conformation in the crystal structure,
using Quanta, and refined using CNX [44].
the tightly bound fatty acids in the LBD, and the ob-
served constitutive activity in cells. Our results suggest
GC/EI/MS
that translated HNF4 spontaneously adopts a transcrip- Lipids were extracted from an aliquot of HNF4 LBD with chloroform/
tionally active conformation after it captures a suitable methanol (2:1 v/v). The extract was dried under argon and then
endogenous fatty acid within the cell. HNF4 then func- dissolved in hexane. The extract was then treated with an aliquot
of methanolic HCL for one hour at room temperature to producetions as a constitutively active transcription factor,
the methyl ester of the hypothesized fatty acids. After the reaction,which is most likely regulated its expression levels, by
the sample was dried again under argon. The derivatized sampleposttranslational modification [39], or by complex for-
was then analyzed by GC/MS on a Finnigan Trace instrument. Ana-
mation with cofactors [10, 40]. lytes were eluted from a 25 m DB1 column by increasing the column
temperature from 100–280C at 12C per minute. Mass spectra were
Experimental Procedures acquired using a scan range of 50–500 Da in 0.5 s. The position of
the double bond was determined by treating some of the HNF4
Subcloning and Protein Purification of HNF4 LBDs extract with 3-pyridyl carbinol (1% in acetonitrile), to produce the
Constructs containing amino acids 103–408 of HNF4 and 142–465 picolinyl ester derivative.
of HNF4 were subcloned into a T7 E. coli expression vector,
pRSETa (Invitrogen) with a His-tag sequence MKKGHHHHHHG en-
NMRgineered at the protein’s N terminus. The plasmids were transformed
A TOCSY-HETCOR spectrum [28] and a 13C reference spectruminto BL21 (DE3) cells which were grown at 22C overnight and then
were acquired on a Varian Inova 500 MHz NMR spectrometer usingharvested. Cells were lysed using a Rannie cell homogenizer, fol-
a Nalorac 3 mm dual probe. The TOCSY-HETCOR spectrum waslowed by centrifugation at 20,000  g for 1 hr. The soluble protein
acquired with spectral widths of 18273 Hz and 2854 Hz in F2 andwas purified with an affinity column of Ni2-NTA coupled Agarose
F1, respectively. Each fid was acquired with an acquisition time of(Qiagen) (25 mM Tris [pH 8.0], 50 mM Imidazole [pH 8.0], 150 mM
0.448 s (8192 complex points), with a total of 320 transients per fid.NaCl). A 50–500 mM imidazole gradient was used for elution with
The number of increments in F1 was 120  2. The TOCSY mixingHNF4 eluting at 100 mM imidazole. For crystallization trials, the
time was 55 ms.eluted protein fractions were pooled and diluted to 25 mM salt
followed by further purification using a POROS 50HQ column (Per-
Septive Biosystems) with a 25–500 mM NaCl gradient. Two peaks FRET Assay
were isolated, one representing homodimers of full-length HNF4 A cell-free ligand-sensing assay using fluorescence resonance en-
LBD, the other containing heterodimers of full-length and C-ter- ergy transfer (FRET) assay [45] was developed utilizing a peptide
minally truncated HNF4. The homodimer peak was concentrated containing the second LXXLL motif (residues 676–700) of the protein
to 20 mg/ml and further purified by gel filtration chromatography in SRC-1 and the HNF4 LBD. HNF4 LBDs were expressed in E. coli
GF buffer (10 mM Tris [pH 8.0], 0.1 mM EDTA, 150 mM NaCl, 10 mM and purified to homogeneity as above, then biotinylated. The SRC-1
DTT, 5% propane-diol) using a Superdex 75 column (AP Biotech). protein was labeled with europium chelate [46] and the HNF4 LBD
Protein sequence and purity were confirmed by N-terminal sequenc- was labeled with the streptavidin-conjugated fluorophore allophy-
ing and mass spectrometry to greater than 95% homogeneity. cocyanin (Molecular Probes). Labeled HNF4 LBD and SRC-1 were
incubated together and the level of interaction was observed by
Crystallization and Data Collection exciting at 340 nm and measuring the fluorescence at 665 nm. The
Crystallization trials were conducted with both the full-length homo- fluorescence signal was reduced by addition of unlabeled HNF4.
dimers and the full-length/truncated heterodimers. The purified pro-
tein was concentrated to 30 mg/ml in GF buffer and crystallized
Construction of HNF4 Expression Plasmidsusing the vapor diffusion method by adding equal volume amounts
Full-length human HNF4 [11] and HNF4 [2] cDNAs were amplifiedof concentrated protein and a crystallization buffer of 0.75 M ammo-
using primers containing a consensus Kozak sequence (ACCACC)nium dihydrogen phosphate/diammonium hydrogen phosphate (pH
flanking the initiator methionine codon as well as flanking EcoRI5.0), 10 mM DTT. Crystals formed within 2–3 weeks and were suitable
and NotI restriction sites. The amplified products were subclonedfor data collection in 7–10 weeks. Crystals were obtained from both
into the pSG5 eukaryotic expression vector (Stratagene, La Jolla,homo- and heterodimeric species.
CA) that contained a modified polylinker region. Mutations of theCrystal were screened for diffraction quality using a rotating anode
HNF4 R187 codon to E187, M187, and A187 were carried out viaX-ray generator (Rigaku RU200) with a Raxis II imaging plate detec-
PCR. Analogous R226 mutations were carried out in the HNF4tor (MSC). Crystals were frozen in liquid nitrogen prior to data collec-
sequence by the same method.tion, after being exchanged into cryo buffer (crystallization buffer
with 30% PEG400). During the exchange, the PEG400 concentration
was increased stepwise by 6% increments to a maximum of 30%. Construction of Reporter Constructs
A HNF4 reporter vector (HNF1x3-tk-CAT) was constructed whichHNF4 LBD crystallized in the space group I4122, with a unit cell of
a  b  152.71 A˚, c  93.42 A˚,       90 with one molecule contained three copies of a DR4 element from the HNF1 promoter
[47]. A double-stranded oligonucleotide containing the followingin the asymmetric unit. Full-length homodimer crystals diffracted
significantly better than crystals of full-length/truncated hetero- sequence: (5-AGCTTGCAAG TCCAAAGTTC GCGCCGCAAG TCC
AAAGTTC GCGCCGCAAG TCCAAAGTTC G) was inserted proximaldimers. A complete 3.0 A˚ native data set was collected on the Raxis
II, followed by screening heavy atom soaks for diffraction quality, to the thymidine kinase minimal promoter of the pBLCAT2 vector
[48] via unique Hind III and Sal I restriction sites.isomorphism, and possible substitution level. An overnight soak
HNF4 Binds Fatty Acids
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Cotransfection Assays Doria, A. (1999). Hepatocyte Nuclear factor-4: cDNA sequence,
gene organization, and mutation screening in early-onset au-CV-1 cells were plated in 96-well plates at a density of 20,000 cells
per well in high glucose DMEM supplemented with 10% charcoal/ tosomal-dominant type 2 diabetes. Diabetes 48, 2099–2102.
12. Hertz, R., Magenheim, J., Berman, I., and Bar-Tana, J. (1998).dextran-treated FBS (HyClone Laboratories, Logan, UT). Transfec-
tion mixes contained 4 ng of HNF4 receptor expression vector, 15 Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-
4. Nature 392, 512–516.ng of HNF1x3-tk-CAT reporter plasmid, 8 ng of a secreted alkaline
phosphatase reporter vector for internal control, and 53 ng of carrier 13. Bogan, A.A., Dallas-Yang, Q., Ruse, M.D., Jr., Maeda, Y., Jiang,
G., Nepomuceno, L., Scanlan, T.S., Cohen, F.E., and Sladek,plasmid. Transfections were performed with Lipofectamine (Life
technologies) in OPTI-MEM medium (Life technologies) essentially F.M. (2000). Analysis of protein dimerization and ligand binding
of orphan receptor HNF4. J. Mol. Biol. 302, 831–851.according to manufacturer’s instructions. Cells were incubated in
the transfection mix for 24 hr followed by an additional 24 hr in 100 14. Bogan, A.A., Cohen, F.E., and Scanlan, T.S. (1998). Natural li-
gands of nuclear receptors have conserved volumes. Nat.
l OPTI-MEM. At the end of the incubation, reporter activities were
assayed as previously described [49]. Struct. Biol. 5, 679–681.
15. Williams, S.P., and Sigler, P.B. (1998). Atomic structure of pro-
gesterone complexed with its receptor. Nature 393, 392–396.Acknowledgments
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